Drug Pipeline

Education is a significant element of comprehensive care for COPD patients. In this Q&A, one expert shares her recommendations.

Finding technology solutions to diagnose and manage chronic conditions is critical to the future of healthcare.

Key takeaways for healthcare executives from Bruno Medeiros, MD, associate professor of medicine (hematology) at the Stanford University Medical Center and director of Cancer Center Infusion Area Treatment Services at Stanford Cancer Center.

FDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.

A University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.

CMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.

Pre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?

External, non-payer generated data can inform formulary decision-making-if payers know their strengths and weaknesses.

The specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.

Value-based insurance designs for diabetes care improve outcomes, but monetary gains may take years.

Recent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.

Acute myeloid leukemia experts share promising new developments on the oncology horizon.

Recent study findings reveal which patients are more likely to be readmitted for COPD problems, and which readmission reduction strategies might work best.

To succeed as a Next Generation ACO, Indiana University Health system is changing its COPD care management approach.

Physicians need to be able to move quickly to care for patients with AML, and they need to have payers on board.

PBMs partnering with pharmacies and drug makers may have a solution to nonadherence due to high pharma costs.

There are several possible reasons that breastfeeding may influence breast cancer risk, according to the American Institute of Cancer Research. Find out what they are.

New research shows that these certain patients with breast cancer can benefit from genetic testing for all breast cancer genes.

The medication’s ability to reduce inflammation sited as one possible explanation.

Study highlights the need for services and research for this understudied population.

Study shows Clovis Oncology’s rucaparib shows clinically meaningful impact in delaying disease recurrence in ovarian cancer.

Understanding genetic variations and tumor differences in black women with breast cancer could lead to personalized diagnosis and treatment.

A new study found that distinguishing between population health and community health strategies can help health organizations define clear goals and earmark the right resources to accomplish them.

New research shows hypertension, diabetes influence survival of ovarian cancer patients in different ways.

Alcohol consumption is known to be a risk factor for breast cancer based on studies predominantly done in white women. Now, a University of North Carolina Lineberger Comprehensive Cancer Center study has found the same risk exists for black women.

A new study provides new insights into the epidemiology of breast cancer among the most prominent Asian-American ethnic groups in California.

New findings reveal this genetic test to assess breast cancer risk could be more effective than others.

From public furor over price hikes to the loss of patent protections for blockbuster drugs, big changes are afoot in the pharmaceutical marketplace. Read more.

Just last year, the FDA approved Exondys 51 (eteplirsen) for DMD, over the recommendations of FDA scientists and an external scientific advisory committee. Read more.

Oncology is a complex and rapidly-evolving management challenge for payers.